Almost exactly one year ago, the World Health Organization (WHO) declared a pandemic because the SARS Cov-2 virus was causing many fatal illnesses around the world at breakneck speed. Since then, much has happened in the medical technology industry to tinker with solutions to protect humans from the virus.
Many companies have developed their own solutions, such as Dräger.
In spring 2021, the company’s portfolio is to be expanded to include a rapid antigen test that is simple, fast, and, above all, hygienic. The smear test takes place only in the anterior nasal region without professional assistance. After a 15-minute waiting period, the result is available. The effectiveness of the test is clinically tested just for professionals and laymen. The product will then receive a CE mark, also for self-application.
The innovative solution developed by scientists at Freie Universität Berlin in cooperation with RWTH Aachen University is an „upper hand mask“ that is self-disinfecting on the inside and outside and allows free breathing. The material, a fiber of the mask, has an aseptic effect and is certified. The fiber is 99.9 percent virus-free. It also has an efficient nano filter built-in. The air to breathe flows freely, but microparticles such as viruses and germs are still filtered out.
As the leading German testing house, the VDE Institute makes it possible to check sterilization devices during the Corona pandemic. It tests all devices with UV-C radiation for effectiveness and safety as well as for disinfection quality.
Günther Zühlsdorf GmbH, based in Berlin, has dedicated itself to mask production during the crisis. Recently, medical-surgical masks have also been produced in cooperation with the Fraunhofer Institute and Pia Automaten GmbH. Production has grown to 30,000 pieces per day in a short time thanks to the right helpers. The certified IIR-type masks are produced with German raw materials and under strict hygiene regulations, a fact that Managing Director Nico Feichtinger is particularly proud of.
Evonik and Biontech are expanding their strategic partnership even further so that larger quantities of vaccines can be produced. Accordingly, Evonik is supplying Biontech with sufficient quantities of the lipids needed for the production of mRNA-based vaccines so that the delivery times for the finished vaccines can be met.
There are also many other innovations that have proven to be effective tools in the course of the Corona pandemic. However, it is not possible to list them all here, so this was just a small excerpt from the medical technology industry ticker.
Source: Devicemed